Loading stock data…
$1.65-0.11 (-6.25%)
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain.
Serina Therapeutics, Inc. in the Healthcare sector is trading at $1.65 with a market capitalization of $51M. Wall Street consensus targets $9.50 (2 analysts), implying a +475.8% move over the next 12 months. The stock is currently near its 52-week low of $1.22, remaining 21.8% below its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 25 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$6.78M↓ | -$6.28M↓ | -$6.21M↑ | -$6.39M↓ | -$5.57M |
| Net Income | -$6.36M↑ | -$6.90M↓ | -$3.34M↑ | -$4.58M↑ | -$6.45M |
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 ...